BiotechTube

Abametapir Lotion 0.74% w/w

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head Lice

Conditions

Head Lice

Trial Timeline

Jan 1, 2014 → Jun 1, 2014

NCT ID
NCT02062073

About Abametapir Lotion 0.74% w/w

Abametapir Lotion 0.74% w/w is a phase 1 stage product being developed by Dr. Reddy's Laboratories for Head Lice. The current trial status is completed. This product is registered under clinical trial identifier NCT02062073. Target conditions include Head Lice.

What happened to similar drugs?

11 of 20 similar drugs in Head Lice were approved

Approved (11) Terminated (0) Active (9)
✅Galcanezumab-GnlmEli LillyApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved
✅Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅Erenumab 70 mg + Erenumab 140 mg + PlaceboAmgenApproved
✅Rimegepant + ZavegepantPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02062073Phase 1Completed

Competing Products

20 competing products in Head Lice

See all competitors
ProductCompanyStageHype Score
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + PlaceboDr. Reddy's LaboratoriesPhase 1
26
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40
Docetaxel + Erlotinib + ChemotherapyAstellas PharmaPhase 2
35